Merete Lund Hetland

Research interests

Publications

• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

  Annals of the Rheumatic Diseases · 2024 · https://doi.org/10.1136/ard-2024-225531

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

  Annals of the Rheumatic Diseases · 2020 · https://doi.org/10.1136/annrheumdis-2019-216655

• A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

  Annals of the Rheumatic Diseases · 2017 · https://doi.org/10.1136/annrheumdis-2016-210742

• EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

  Annals of the Rheumatic Diseases · 2016 · https://doi.org/10.1136/annrheumdis-2016-209846

• FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2014-eular.3004

• Inequities in access to biologic and synthetic DMARDs across 46 European countries

  Annals of the Rheumatic Diseases · 2013 · https://doi.org/10.1136/annrheumdis-2012-202603

• Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

  Arthritis & Rheumatism · 2013 · https://doi.org/10.1002/art.37876

• Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

  Annals of the Rheumatic Diseases · 2011 · https://doi.org/10.1136/ard.2010.148759

• Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

  Arthritis & Rheumatism · 2010 · https://doi.org/10.1002/art.30117

• Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

  Annals of the Rheumatic Diseases · 2010 · https://doi.org/10.1136/ard.2009.124446

• Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

  Arthritis & Rheumatism · 2009 · https://doi.org/10.1002/art.27227

• Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database

  Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2009.109983

• MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

  Annals of the Rheumatic Diseases · 2008 · https://doi.org/10.1136/ard.2008.088245

• Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis.

  PubMed · 2008

• QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

  Annals of the Rheumatic Diseases · 2007 · https://doi.org/10.1136/ard.2006.069252

• Health in Old Age: How Do Physicians' Ratings and Self-ratings Compare ?

  Journal of Gerontology · 1979 · https://doi.org/10.1093/geronj/34.5.687

Current projects

No projects listed.